Document is current
Any future updates will be listed below
-
Authors
Scicluna, Brendon P. https://orcid.org/0000-0003-2826-0341
Cano-Gamez, Kiki
Burnham, Katie L. https://orcid.org/0000-0001-8680-2933
Davenport, Emma E.
Moore, Andrew Reese https://orcid.org/0000-0001-8040-2576
Khan, Soumen https://orcid.org/0000-0002-6012-2232
Hinds, Charles J. https://orcid.org/0000-0001-5094-8324
Cremer, Olaf L. https://orcid.org/0000-0003-4264-1108
Khatri, Purvesh https://orcid.org/0000-0002-4143-4708
Sweeney, Timothy E. https://orcid.org/0000-0002-3596-1093
Knight, Julian C. https://orcid.org/0000-0002-0377-5536
van der Poll, Tom https://orcid.org/0000-0002-9199-5079
- License Information
-
More Information
Article History
Received: 20 November 2024
Accepted: 15 August 2025
First Online: 30 September 2025
Competing interests
: P.K. is co-founder, consultant to and a scientific adviser to Inflammatix. T.E.S. is co-founder, employee of and shareholder in Inflammatix. O.L.C. received in kind and in cash contributions to research from ImmuneXpress (2015–2019), Abionic (2021–2022), Prolira (2022–2024) and Presymptom Health (2023–2026). E.E.D. and K.L.B. report that the Wellcome Sanger Institute is supported by core funding from the Wellcome Trust (206194, 220540/Z/20/A). J.C.K. and K.C.-G. report funding from a grant to their institution from the Danaher Beacon Programme for work on RNA biomarker point-of-care test development for SRS in sepsis. T.v.d.P. reports research grants from the EU’s Horizon 2020 programme (FAIR, Immunosep), Inflammatix and the Ministry of Economic Affairs & Health Holland (all paid to the institution). For the purpose of open access, the authors have applied a CC BY public copyright license to any author-accepted manuscript version arising from this submission. The other authors declare no competing interests.
